Verrica Pharmaceuticals Inc. (VRCA)
| Market Cap | 103.76M +74.4% |
| Revenue (ttm) | 37.16M +417.6% |
| Net Income | -17.83M |
| EPS | -1.31 |
| Shares Out | 17.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 60,525 |
| Open | 6.30 |
| Previous Close | 6.15 |
| Day's Range | 6.00 - 6.80 |
| 52-Week Range | 3.28 - 9.82 |
| Beta | 1.49 |
| Analysts | Strong Buy |
| Price Target | 15.54 (+157.29%) |
| Earnings Date | May 12, 2026 |
About VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of... [Read more]
Financial Performance
In 2025, Verrica Pharmaceuticals's revenue was $35.58 million, an increase of 370.22% compared to the previous year's $7.57 million. Losses were -$17.89 million, -76.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for VRCA stock is "Strong Buy." The 12-month stock price target is $15.54, which is an increase of 157.29% from the latest price.
News
Verrica Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
YCANTH has seen improved access and growing adoption, with Q1 revenue at $4.3 million and over 100,000 applicator units dispensed. The pipeline includes a phase III common warts program (50% enrolled) and a BCC program with strong phase II results. Cash runway extends into Q1 2027.
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of derm...
Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Verrica Pharmaceuticals (VRCA) with a Buy rating and $12 price target The company reported “encouraging” Ycanth volume in Q1, the analyst tells investors in a…
Verrica Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
YCANTH has achieved strong commercial growth with expanding market penetration and robust support programs. International expansion is progressing, and the pipeline includes a large common warts program and a promising basal cell carcinoma candidate, VP-315, with significant clinical and commercial potential.
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of derm...
Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)
Reports Q1 revenue $5.02M, consensus $4.52M. “Our first quarter performance reflects accelerating growth in market demand for YCANTH as the new standard of care for the treatment of molluscum contagio...
Verrica Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw record growth in YCANTH demand, with revenue up 25% year-over-year and strong momentum into Q2. The company advanced its clinical pipeline, launched YCANTH in Japan, and is preparing for EU expansion, while maintaining a solid cash position to fund operations into 2027.
Verrica Pharmaceuticals Earnings release: Q1 2026
Verrica Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Verrica Pharmaceuticals Quarterly report: Q1 2026
Verrica Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed...
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verric...
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the ...
Verrica Pharmaceuticals Proxy statement: Proxy filing
Verrica Pharmaceuticals filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Verrica Pharmaceuticals Proxy statement: Proxy filing
Verrica Pharmaceuticals filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Verrica Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
YCANTH continues to drive revenue growth through expanded access and clinician adoption, with a robust pipeline targeting common warts and basal cell carcinoma. Phase III trials for both indications are progressing, supported by strong financials and strategic partnerships.
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of de...
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of de...
Verrica Pharmaceuticals Slides: Corporate presentation
Verrica Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on March 27, 2026.
Verrica Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 saw a dramatic turnaround with over 130% YCANTH revenue growth, a 368% rise in total revenue, and a strengthened balance sheet. Clinical and commercial progress positions the company for further expansion in 2026, with ongoing global trials and new market entries.
Verrica Pharmaceuticals Annual report: Q4 2025
Verrica Pharmaceuticals has published its Q4 2025 annual report on March 11, 2026.
Verrica Pharmaceuticals Earnings release: Q4 2025
Verrica Pharmaceuticals released its Q4 2025 earnings on March 11, 2026, summarizing the period's financial results.
Verrica Pharmaceuticals reports Q4 adjusted EPS (51c), consensus (79c)
Reports 4Q revenue $5.092M, consensus $4.52M. “In 2025, Verrica successfully implemented a series of transformational changes that we believe have fundamentally improved the future growth and strategi...
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenu...
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications fo...
Verrica Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
YCANTH has rapidly gained adoption by addressing a major unmet need in molluscum contagiosum, with expanded access, streamlined distribution, and a growing, collaborative sales force. The pipeline includes a phase III program for common warts and a promising Basal Cell Carcinoma candidate, supporting long-term growth.